PHARMACYTE BIOTECH, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
PHARMACYTE BIOTECH, INC. (PMCB) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$4.08 million for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-29.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-07-29
- PHARMACYTE BIOTECH, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2026 was -$4.08M, a 163.36% decline from fiscal 2025.
- PHARMACYTE BIOTECH, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was $6.44M, a 9085.01% increase from fiscal 2024.
- PHARMACYTE BIOTECH, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was $70.09K.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2026-04-30 | -$4.08M 10-K · filed 2026-07-29 |
| 2025-04-30 | $6.44M 10-K · filed 2026-07-29 |
| 2024-04-30 | $70.09K 10-K · filed 2025-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |